AMARIN CORP PLCUK
Price data unavailable
Track AMRN in your trading journalAbout AMARIN CORP PLCUK
AMRN is the ticker symbol for AMARIN CORP PLCUK, a publicly traded US company.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
Key metrics include a return on equity of -2.3%, a debt-to-equity ratio of 0.44.
The company reports trailing twelve-month revenue of $43.92M and net loss of $10.51M.
FINOTAUR aggregates real-time and fundamental data on AMRN to help traders and investors make informed decisions. Track AMRN in your trading journal alongside other positions for a unified view of your portfolio.
Fundamentals
| Revenue (TTM) | $43.92M |
| Net Income (TTM) | $-10.51M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -2.34% |
| Debt-to-Equity | 0.44 |
| Dividend per Share | — |
Recent News
- The Motley Fool·Mar 7
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks
- GlobeNewswire Inc.·Nov 11
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
- GlobeNewswire Inc.·Nov 9
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
Want real-time analysis on AMRN?
Track it free in your trading journal. Log trades, tag setups, and review your edge.